Saturday, March 17, 2018

FINANCIAL TOXICITY, Part 1


Linda and Sue Broadhurst
at Sue's wedding

Remember my suggestion that a large fraction of Liberal Arts graduates go to work for the federal government – and spend the rest of their lives writing reports?  Well, PhDs and M.Ds write reports, too.  Here is an important one.


In a nutshell, a learned panel considered the following question – “How can we afford cancer treatment?” – and came up with a lengthy discussion of possibilities.  I was prepared to use some cute adjectives – “turgid”, perhaps, or “bureaucratic”, or even “annoying” – but they don’t fit.  The report is long, but it is well written, well organized, well-illustrated, and even thoughtful.  I intend to study it carefully and give you my take in a few days (too busy right now, what with my mad social life and all.)  You might give it a try.  To whet your appetite:

The average yearly cost of new cancer drugs is $100,000.  Some go as high as $400,000. 

Some of these drugs are truly transformative, but others only provide a few more months of life.

Urgently needed is a way to process drug effectiveness into pricing policy.

I love the term in introduced by the panel – “Financial Toxicity”.




No comments:

Post a Comment